Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)

v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
segment
shares
Dec. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
shares
Number of Operating Segments | segment             2    
Proceeds from Divestiture of Interest in Consolidated Subsidiaries               $ 17,824  
Revenue from Contract with Customer, Excluding Assessed Tax       $ 272,598 $ 271,581   $ 549,533 541,236  
Gain on sale of Eminence             0 $ 11,682  
Gain (loss) on equity method investment       $ (1,914)     (4,204)    
Positions eliminated during the period as a percentage       4.00%          
Current liabilities attributable to disposal group held for sale       $ 1,593     1,593    
Impairment of Long-Lived Assets to be Disposed of             $ 6,038    
Common stock, shares authorized (in shares) | shares       400,000,000     400,000,000   400,000,000
Eminence Biotechnology                  
Proceeds from Divestiture of Interest in Consolidated Subsidiaries   $ 17,800              
Protein Sciences                  
Goodwill attributable to disposal group held for sale       $ 1,400     $ 1,400    
Current liabilities attributable to disposal group held for sale       1,600     1,600    
Pre-tax restructuring charges       130     220   $ 1,700
Protein Sciences | Current Assets, Held For Sale                  
Inventory attributable to disposal group       11,300     11,300    
Property, plant and equipment attributable to disposal group held for sale       5,600     5,600    
Intangible assets, excluding goodwill, attributable to disposal group held for sale       14,300     14,300    
Protein Sciences | Eminence Biotechnology                  
Revenue from Contract with Customer, Excluding Assessed Tax           $ 2,000      
Wilson Wolf Corporation                  
Investment percentage 19.90%                
Gain (loss) on equity method investment       (1,900)     (4,300)    
Investment amount       $ 250,000     $ 250,000    
Payments to Acquire Investments $ 232,000   $ 25,000            
Forward Contract, Milestone, Multiple for Total Expected Payments       4.4     4.4    
Wilson Wolf Corporation | First Part of Forward Contract                  
Forward Contract, Milestone, Annual Revenue Required       $ 92,000     $ 92,000    
Forward Contract, Milestone, Annual EBITDA       55,000     55,000    
Wilson Wolf Corporation | Second Part of Forward Contract                  
Forward Contract, Milestone, Annual Revenue Required       226,000     226,000    
Forward Contract, Milestone, Annual EBITDA       136,000     136,000    
Forward Contract, Additional Investment       1,000,000     $ 1,000,000    
Selling, General and Administrative Expenses | Protein Sciences                  
Asset Impairment Charges       $ 6,000          
QT Holdings Corporation | Protein Sciences                  
Pre-tax restructuring charges                 $ 2,200
Eminence Biotechnology | Nonoperating Income (Expense)                  
Gain on sale of Eminence           $ 11,700